Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Olanzapine plus fluoxetine: Phase III; Under FDA review

In an 8-week, double-blind, placebo-controlled U.S. Phase III trial in 833 patients, the estimated median time to a partial response for OFC patients

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE